1. Serum thymidine kinase 1 protein concentration for predicting early progression and monitoring the response to TACE in hepatocellular carcinomas: a network meta-analysis
- Author
-
Sven Skog, Jin Li, Ji Zhou, Hongbo Ma, Ailian Hei, and Ellen He
- Subjects
TACE ,business.industry ,STK1p ,pre-HCC ,digestive system diseases ,03 medical and health sciences ,0302 clinical medicine ,030220 oncology & carcinogenesis ,Meta-analysis ,TK1 ,Cancer research ,Medicine ,030211 gastroenterology & hepatology ,Clinical significance ,HCC ,business ,Thymidine kinase 1 ,Protein concentration ,neoplasms ,NMA ,Biotechnology ,Research Article - Abstract
Aim: A meta-analysis was conducted to evaluate the clinical significance of serum thymidine kinase 1 protein concentration (STK1p) in distinguishing between hepatocellular carcinomas (HCC) and non-HCC for predicting early progression and monitoring the response to transarterial chemoembolization in HCC. Materials & methods: A total of 24 eligible studies were included, containing 1849 HCC patients and 1069 healthy subjects. Results: The STK1p level significantly increased from normal controls to benign/pre-HCC and HCC (p, Lay abstract There is a need for reliable prognostic biomarkers in liver cancer, to support therapy efforts. In this study we investigated if thymidine kinase 1 in blood could be used to discover patients with hepatocellular carcinoma and show the results of their treatment. The results are based on 1847 hepatocellular carcinoma patients and 1069 healthy people. We conclude that serum thymidine kinase 1 protein concentration is a reliable biomarker in liver cancer.
- Published
- 2021